Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cetermin - Insmed

X
Drug Profile

Cetermin - Insmed

Alternative Names: Betakine; Recombinant transforming growth factor-beta-2; TGF-beta-2; Transforming growth factor-beta-2

Latest Information Update: 31 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Insmed
  • Developer Enzon Pharmaceuticals; Insmed; Sanofi
  • Class Transforming growth factors
  • Mechanism of Action Immunosuppressants; Intercellular signalling peptide and protein stimulants; Osteogenesis stimulants; Transforming growth factor beta2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Age-related macular degeneration; Autoimmune disorders; Cancer; Diabetic foot ulcer; Eye disorders; Multiple sclerosis; Pleural effusion; Postmenopausal osteoporosis; Rheumatoid arthritis; Skin disorders; Transplant rejection

Most Recent Events

  • 10 Jan 2006 Discontinued - Phase-I for Multiple sclerosis in USA (IV)
  • 10 Jan 2006 Discontinued - Phase-II for Diabetic foot ulcer in USA (unspecified route)
  • 10 Jan 2006 Discontinued - Preclinical for Pleural effusion in Australia (unspecified route)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top